Partners

• 
   

  UCB

  UCB
  Pharma
  S.A.
  
  (EFPIA
  member
  company)

  
  UCB

  • 
    
    P1
    UCB
    
    is
    a
    global
    biopharmaceutical
    company
    focused
    on
    the
    discovery
    and
    development
    of
    innovative
    medicines
    and
    solutions
    to
    transform
    the
    lives
    of
    people
    living
    with
    severe
    diseases
    of
    the
    immune
    system
    or
    of
    the
    central
    nervous
    system.
    UCB
    has
    operations
    in
    approximately
    40
    countries
    and
    global
    revenue
    of
    €
    3.4
    billion
    in
    2012.
    UCB
    has
    drugs
    in
    development
    for
    the
    treatment
    of
    Rheumatoid
    Arthritis
    and
    SLE.
    UCB
    is
    committed
    to
    the
    development
    of
    disease
    modifying
    drugs
    for
    auto-immune
    diseases.
    The
    leadership
    for
    this
    IMI
    project
    is
    drawn
    from
    Department
    of
    Global
    Exploratory
    Development
    who
    are
    based
    in
    the
    UK
    and
    Belgium.
  • 
    
    Role
    in
    the
    project
    
    Coordinator,
    Leader
    of
    WP1,
    Co-leader
    of
    WP6
    and
    WP9
    ,
    Participant
    in
    WP2,
    WP4,
    WP7,
    and
    WP8.

• 
   

  FPS

  Fundación
  Pública
  Andaluza
  Progreso
  y
  Salud
  (GENYO)

  
  FPS

  • 
    
    P2
    FPS
    (GENYO)
    
    is
    a
    mixed
    centre
    with
    stakes
    held
    by
    the
    Regional
    Ministry
    of
    Economy,
    Innovation,
    Science
    and
    Employment,
    the
    Regional
    Ministry
    of
    Equality,
    Health
    and
    Social
    Policies,
    the
    University
    of
    Granada
    and
    the
    pharmaceutical
    company
    Pfizer.
    This
    centre
    has
    been
    devised
    as
    a
    space
    for
    excellence
    research
    in
    genomic
    medicine,
    focussing
    on
    the
    comprehensive
    study
    and
    understanding
    of
    the
    genetic
    basis
    of
    human
    diseases
    in
    general,
    placing
    special
    emphasis
    on
    cancer
    and
    its
    genetic
    disorders
    related
    to
    inheritance.
    This
    centre
    is
    the
    benchmark
    centre
    of
    the
    Andalusian
    Program
    for
    Research
    in
    Clinical
    Genetics
    and
    Genomic
    Medicine,
    a
    program
    which,
    together
    with
    those
    of
    Cell
    Therapy
    and
    Regenerative
    Medicine,
    and
    Nanomedicine
    have
    the
    main
    objective
    of
    supporting
    and
    fostering
    translational
    research
    in
    Advanced
    Therapies.
    The
    activities
    performed
    within
    these
    three
    research
    programs
    are
    developed
    in
    coordination
    with
    the
    Andalusian
    Initiative
    for
    Advanced
    Therapies
    (IATA),
    an
    initiative
    of
    the
    Andalusian
    Government
    promoted
    by
    the
    Regional
    Ministries
    of
    Health
    and
    Innovation,
    Science
    and
    Enterprise.
  • 
    
    Role
    in
    the
    project
    
    Managing
    Entity,
    Leader
    of
    WP2
    and
    WP9,
    Co-leader
    WP1,
    Participant
    in
    WP4,
    WP5,
    WP6,
    and
    WP8.

• •  

  Althia

  Althia
  Health,
  S.L.
  
  (SME)

  
  Althia

  • 
    
    P3
    Althia
    
    is
    a
    company
    dedicated
    to
    the
    Personalised
    Predictive
    Oncology.
    Althia
    specializes
    in
    generating
    knowledge
    to
    improve
    the
    comprehensive
    management
    of
    cancer
    patients.
    Operates
    in
    three
    areas:
    1)
    Clinical
    Diagnostics/Prognostics
    Services
    in
    hematological
    and
    solid
    tumors,
    to
    public
    and
    private
    hospitals,
    and
    laboratories;
    2)
    R&D
    translational
    projects
    in
    collaboration
    with
    leading
    centers
    to
    identify
    molecular
    patterns
    in
    order
    to
    allow
    selection
    of
    patients
    responding
    to
    a
    given
    therapy;
    and
    3)
    treatment
    by
    single
    dose
    image-guided
    radiation
    therapy
    (SD-IGRT),
    being
    implemented
    at
    the
    facilities
    of
    the
    Hospital
    Recoletas
    Campo
    Grande.
  • 
    
    Role
    in
    the
    project
    
    Participant
    in
    WP1,
    WP7,
    and
    WP9.

• 
   

  CHP

  Centro
  Hospitalar
  do
  Porto.
  UMIB

  
  CHP

  • 
    
    P4
    CHP
    
    Centro
    Hospitalar
    do
    Porto.
    UMIB,
    Instituto
    de
    Ciência
    Biomédicas
    Abel
    Salazar.
    Universidade
    do
    Porto.
    UMIB
    is
    based
    in
    a
    Medical
    School,
    the
    Institute
    of
    Biomedical
    Sciences
    Abel
    Salazar,
    University
    of
    Porto
    and
    its
    University
    Hospital,
    the
    Hospital
    de
    Santo
    António
    at
    Centro
    Hospitalar
    do
    Porto.
    To
    achieve
    its
    goals
    UMIB
    has
    multidisciplinary
    teams
    of
    researchers
    from
    different
    branches
    of
    basic
    science
    and
    clinical
    medicine,
    with
    diverse
    technical
    and
    scientific
    skills,
    which
    guarantee
    the
    possibility
    of
    using
    different
    approaches
    to
    achieve
    a
    common
    objective,
    thus
    creating
    the
    basis
    for
    the
    establishment
    of
    Translational
    Research
    programs.
  • 
    
    Role
    in
    the
    project
    
    Participant
    in
    WP1,
    WP2,
    WP3,
    WP5,
    and
    WP9.

• 
   

  CSIC

  Consejo
  Superior
  de
  Investigaciones
  Científicas

  
  CSIC

  • 
    
    P5
    CSIC
    
    is
    the
    largest
    public
    institution
    dedicated
    to
    research
    in
    Spain
    and
    the
    third
    largest
    in
    Europe.
    Belonging
    to
    the
    Spanish
    Ministry
    of
    Economy
    and
    Competitiveness
    through
    the
    Secretary
    of
    State
    for
    Research,
    Development
    and
    Innovation,
    its
    main
    objective
    is
    to
    develop
    and
    promote
    research
    that
    will
    help
    bring
    about
    scientific
    and
    technological
    progress,
    and
    it
    is
    prepared
    to
    collaborate
    with
    Spanish
    and
    foreign
    entities
    in
    order
    to
    achieve
    this
    aim.
    The
    Institute
    of
    Parasitology
    and
    Biomedicine
    López-Neyra
    (IPBLN)
    forms
    part
    of
    the
    Spanish
    National
    Research
    Council
    (CSIC)
    and
    its
    activity
    is
    devoted
    to
    research
    in
    the
    area
    of
    biomedical
    sciences.
    The
    fields
    of
    research
    cover
    a
    wide
    range
    of
    issues
    concerning
    immunology,
    cell
    biology,
    molecular
    biology
    and
    pharmacology
    of
    important
    world-wide
    biomedical
    problems.
  • 
    
    Role
    in
    the
    project
    
    Leader
    of
    WP4,
    Participant
    in
    WP1,
    WP8,
    and
    WP9.

  
  
  
  Institute
  of
  Parasitology
  and
  Biomedicine
  López-Neyra
  

• 
   

  IRCCS

  Fondazione
  IRCCS
  Ca
  Granda
  Ospedale
  Maggiore
  Policlinico

  
  IRCCS

  • 
    
    P6
    IRCCS
    
    FONDAZIONE
    IRCCS
    CA’
    GRANDA
    OSPEDALE
    MAGGIORE
    POLICLINICO-
    POLI.
    Public
    Hospital
  • 
    
    Role
    in
    the
    project
    
    Leader
    of
    WP3,
    Participant
    in
    WP1,
    WP2,
    WP5,
    and
    WP9.

• 
   

  IDIBELL

  Fundacio
  Institut
  D’investigacio
  Biomedica
  De
  Bellvitge

  
  IDIBELL

  • 
    
    P7
    IDIBELL
    
    Bellvitge
    Biomedical
    Research
    Institute
    (IDIBELL)
    is
    a
    research
    centre
    focused
    on
    cellular
    medicine,
    where
    the
    high-level
    basic
    research
    focuses
    and
    works
    on
    relevant
    clinical
    matters
    and
    fosters
    economic
    development.IDIBELL
    is
    a
    foundation
    created
    in
    2004
    from
    the
    merger
    of
    several
    research
    entities.
    The
    centre
    manages
    the
    research
    of
    the
    Bellvitge
    University
    Hospital,
    the
    Institut
    Català
    d’Oncologia
    (Catalan
    Institute
    of
    Oncology)
    and
    the
    University
    of
    Barcelona.
    The
    Institute
    is
    integrated
    at
    Biopol’H
    area.In
    2009,
    it
    became
    one
    of
    the
    first
    five
    Spanish
    research
    centres
    accredited
    as
    health
    research
    institute
    by
    the
    Instituto
    de
    Salud
    Carlos
    III
    (Health
    Institute
    Carlos
    III).
  • 
    
    Role
    in
    the
    project
    
    Participant
    in
    WP1,
    WP4,
    WP5,
    WP8,
    and
    WP9.

• 
   

  SCS

  Servicio
  Cantabro
  de
  Salud
  Hospital
  Universitario
  Marqués
  de
  Valdecilla

  
  SCS

  • 
    
    P8
    SCS
    
    SERVICIO
    CÁNTABRO
    DE
    SALUD,
    HOSPITAL
    UNIVERSITARIO
    MARQUÉS
    DE
    VALDECILLA-
    HUMV:
    Public
    Hospital
  • 
    
    Role
    in
    the
    project
    
    Participant
    in
    WP1,
    WP2,
    WP3,
    and
    WP9.

Project
Partners

• 
   
  

  UCB

  UCB Pharma S.A.
  (EFPIA
  member company)
• 
   
  

  FPS

  Fundación Pública
  Andaluza
  Progreso y Salud
  (GENYO)
• 
   
  

  Althia

  Althia Health,
  S.L.
  
  (SME)
• 
   
  

  CHP

  Centro Hospitalar
  do Porto. UMIB
• 
   
  

  CSIC

  Consejo Superior
  de
  Investigaciones
  Científicas
• 
   
  

  IRCCS

  Fondazione IRCCS
  Ca Granda
  Ospedale
  Maggiore
  Policlinico
• 
   
  

  IDIBELL

  Fundacio Institut
  D’investigacio
  Biomedica De
  Bellvitge
• 
   
  

  SCS

  Servicio Cantabro
  de Salud
  Hospital
  Universitario
  Marqués de
  Valdecilla